• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    SC 13G/A 1 s013024a.htm SCHEDULE 13G/A, (AMENDMENT NO. 2)



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549




    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*





    Revvity, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    714046109

    (CUSIP Number)



    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)





    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    CUSIP No. 714046109
    SCHEDULE 13G
    Page 2 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
    Select Equity Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    5,174,224
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    5,174,224
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    5,174,224
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     4.3%*
    12
    TYPE OF REPORTING PERSON
     
    IA
    * Beneficial ownership based on 121,702,145 shares of common stock outstanding as of November 1, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2024.



    2

    CUSIP No. 714046109
    SCHEDULE 13G
    Page 3 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
    George S. Loening
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    5,174,224
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    5,174,224
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    5,174,224
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.3%*
    12
    TYPE OF REPORTING PERSON
     
    IN/HC
    * Beneficial ownership based on 121,702,145 shares of common stock outstanding as of November 1, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 6, 2024.
    3

    Item 1(a)
    Name of Issuer:
       
     
    Revvity, Inc.
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    77 4th Avenue
     
    Waltham, Massachusetts 02451
       
       
    Items 2(a)
    Name of Person Filing:
       
     
    This Schedule 13G is being filed jointly by Select Equity Group, L.P., a Delaware limited partnership (“Select LP”), and George S. Loening (“Loening”), who is the majority owner of Select LP and managing member of its general partner. Select LP and Loening are sometimes collectively referred to herein as the “Select Reporting Persons.”
       
    Item 2(b)
    Address of Principal Business Office:
       
     
    The business address of each of the Select Reporting Persons is:
     
    380 Lafayette Street, 6th Floor
     
    New York, New York 10003
       
    Item 2(c)
    Citizenship:
       
     
    George S. Loening is a United States citizen.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Common Stock
       
    Item 2(e)
    CUSIP Number:
       
     
    714046109
       
       
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:

    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)
    ☒ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)
    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)
    ☒ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)
    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).


    4

    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Select Reporting Person and is incorporated herein by reference for each such Select Reporting Person.
       
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
       
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    See Exhibit 99.1
       
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
       
    Item 10
    Certification:
       
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.




    5




    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


     
    SELECT EQUITY GROUP, L.P.
       
     
    By: Select Equity GP, LLC, its General Partner
       
     
    By: /s/ George S. Loening
     
    Name: George S. Loening
     
    Title: Managing Member
       
       
       
     
    /s/ George S. Loening
     
    George S. Loening, an individual
       
       
    Dated: November 14, 2024
     





    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    SEC Filings

    View All

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    8/5/25 4:10:32 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    7/28/25 7:12:47 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 11-K filed by Revvity Inc.

    11-K - REVVITY, INC. (0000031791) (Filer)

    6/20/25 2:18:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity to Present at Upcoming Investor Conferences

    Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor relations & ESG Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will

    8/18/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

    Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research Revvity, Inc. (NYSE:RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitiv

    8/6/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Vohra Tajinder S gifted 12,183 shares and received a gift of 12,183 shares, decreasing direct ownership by 54% to 10,442 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 5:10:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Officer Victor Miriame

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 4:51:41 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Officer Krakowiak Maxwell

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/18/25 4:05:05 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity upgraded by UBS with a new price target

    UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

    5/1/25 7:42:49 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Bernstein with a new price target

    Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

    1/10/25 8:41:17 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity upgraded by BofA Securities with a new price target

    BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

    12/13/24 8:43:02 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

    7/24/25 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, July 28, 2025

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo

    7/7/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials